Aeovian Pharmaceuticals brings in $37 million in mTOR play
San Francisco-based Aeovian Pharmaceuticals has banked $37 million in Series A financing to launch its mTORC1 inhibitor into a proof-of-concept for what the company says is an undisclosed rare CNS disease.
Linked to a number of aging and nutrient-sensing processes, the mTOR pathway has typically been seen as a rich target for pharmaceutical companies hoping to make inroads in lifespan/healthspan extension. The secrecy behind the ‘undisclosed disease’ is not unusual in a field where research is often painted with the broad brush of ‘age-related diseases.’ Part of Aeovian’s IP comes from the Buck Institute in Novato, California, an independent research institute dedicated solely to studying connections between aging and chronic disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.